Risk Factors That Affect Life Expectancy in Alzheimer's Disease: A 15-Year Follow-Up
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Backgrounds/Aims: Future disease-modifying therapies might affect the expected life span in Alzheimer's disease (AD). Our aim was to identify factors that influence life expectancy in cholinesterase inhibitor (ChEI)-treated patients. Methods: This study included 791 deceased individuals with a clinical diagnosis of AD and a Mini-Mental State Examination score of 10-26 at baseline who were recruited from a 3-year, prospective, multicenter study of ChEI therapy in clinical practice. The participants' date of death was recorded and their survival was compared with the gender- and age-matched general population. Results: The mean survival time after the start of ChEI therapy (time of AD diagnosis) was 5.10 years for men and 6.12 years for women. Better cognitive ability, less impaired basic functional capacity, and fewer medications, but not education level or apolipoprotein E (APOE) genotype, were independent prognostic factors of longer survival after diagnosis, after controlling for gender and age. Conclusion: AD shortens life expectancy in ChEI-treated patients diagnosed before the age of 85 years, similar to that reported previously for untreated individuals. A longer life span was observed in the eldest patients (≥85 years) compared with untreated cohorts, which did not differ from that observed in the general population. Higher education or carrying two APOE ε4 alleles were risk factors for earlier death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ott, A., Breteler, M. M. B., van Harskamp, F., Claus, J. J., van der Cammen, T. J. M., Grobbee, D. E., & Hofman, A. (1995) · BMJ · doi:10.1136/bmj.310.6985.970 · Cited by 792
Education modifies the relation of AD pathology to level of cognitive function in older persons
Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Mendes de Leon, C. F., Arnold, S. E., Barnes, L. L., & Bienias, J. L. (2003) · Neurology · doi:10.1212/01.wnl.0000069923.64550.9f · Cited by 549 · cited 1×
“Therefore, it is assumed that those individuals require a relatively larger burden of AD pathology at the onset of clinical symptoms [30] .”
Stern, Y., Tang, M. X., Denaro, J., & Mayeux, R. (1995) · Annals of Neurology · doi:10.1002/ana.410370508 · Cited by 252
Brodaty, H., Seeher, K., & Gibson, L. (2012) · International Psychogeriatrics · doi:10.1017/s1041610211002924 · Cited by 248 · cited 1×
“In addition, comparisons of survival in AD with life expectancy in the general population and reports of potential differences in the length of life according to AD stage are scarce [11] .”
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152
Agüero‐Torres, H., Fratiglioni, L., Guo, Z., Viitanen, M., & Winblad, B. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02464.x · Cited by 147 · cited 1×
“This finding is not conclusive, as associations between lower education and increased mortality [34] , as well as higher education and increased mortality [15] , have been reported.”
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84 · cited 1×
“The SATS is a prospective, open-label, observational, nonrandomized, multicenter study that has been described in several publications [18–21] .”
Cited by
Sex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.04.001 · Cited by 570
“Previous studies on the length of the AD dementia stage reported a duration of 3–10 years [14,15].”
BackgroundAnti-inflammatories in Alzheimer’s disease—potential therapy or spurious correlate?
Rivers-Auty, J., Mather, A. E., Peters, R., Lawrence, C. B., & Brough, D. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa109 · Cited by 130
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Survival time tool to guide care planning in people with dementia
Haaksma, M. L., Eriksdotter, M., Rizzuto, D., Leoutsakos, J.-M. S., Olde Rikkert, M. G. M., Melis, R. J. F., & Garcia-Ptacek, S. (2020) · Neurology · doi:10.1212/wnl.0000000000008745 · Cited by 95
“A 15-year follow-up study of people with dementia treated with cholinesterase inhibitors showed that impaired daily functioning and greater number of medications are associated with shorter survival after AD diagnosis.(26) Other previously reported risk factors for mortality in older people with and without dementia a…”
Background
Metadata
- Authors
- Wattmo, C., Londos, E., & Minthon, L.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 38
- Issue
- 5-6
- Pages
- 286-299
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W1972662390
- Cited by
- 60
- References
- 8
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.